Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes

Recruiting

• Conditions: Glioma; Immune Suppression
• Interventions: Other: Detection of Immune and Inflammatory Indices in Peripheral Blood

• Registration Number: NCT05635435
• Lead Sponsor: Sun Yat-sen University

Brief Summary

Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10-13
• Primary Completion: 2022-04-06
• Study First Submitted: 2022-11-21
• Study First Submitted QC: 2022-11-22
• Study First Posted: 2022-12-02
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-10
• Last Update Posted: 2023-07-12
• Study Completion: 2023-12-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1282

Inclusion Criteria

• glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria;
• age > 18 years;
• primary malignant glioma;
• the duration of follow-up > 3 months;
• available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization.

Exculsion Criteria:

• current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition;
• prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
primary glioma patients	Detection of Immune and Inflammatory Indices in Peripheral Blood	We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.

Primary Outcome Measures

Name	Time	Method
all-cause mortality	16 years	For this study, the endpoint was all-cause mortality. Time zero was set at the time of resection of the primary tumor.

Trial Locations

Locations (3)

Xuanwu Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China

Sun Yat-sen University Cancer Center; 🇨🇳 Guanzhou, Guangdong, China

The First Bethune Hospital of Jilin University; 🇨🇳 Chang chun, Jilin, China